Difference between revisions of "Voxelotor (Oxbryta)"
Jump to navigation
Jump to search
m |
m |
||
| Line 7: | Line 7: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
*11/25/2019: Granted accelerated approval for the treatment of [[Sickle cell anemia|sickle cell disease]] in adults and pediatric patients 12 years of age and older. | *11/25/2019: Granted accelerated approval for the treatment of [[Sickle cell anemia|sickle cell disease]] in adults and pediatric patients 12 years of age and older. | ||
| + | |||
| + | ==History of changes in EMA indication== | ||
| + | *2/14/2022: Initial EMA authorization | ||
==Also known as== | ==Also known as== | ||
| Line 14: | Line 17: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Sickle cell anemia medications]] | [[Category:Sickle cell anemia medications]] | ||
| + | [[Category:EMA approved in 2022]] | ||
[[Category:FDA approved in 2019]] | [[Category:FDA approved in 2019]] | ||
[[Category:Stub]] | [[Category:Stub]] | ||
Revision as of 12:39, 30 December 2022
Mechanism of action
hemoglobin S polymerization inhibitor
Diseases for which it is used
History of changes in FDA indication
- 11/25/2019: Granted accelerated approval for the treatment of sickle cell disease in adults and pediatric patients 12 years of age and older.
History of changes in EMA indication
- 2/14/2022: Initial EMA authorization
Also known as
- Code names: GBT-440, GTx-011
- Brand name: Oxbryta